Jane Bryce

3.0k total citations · 1 hit paper
41 papers, 1.8k citations indexed

About

Jane Bryce is a scholar working on Oncology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jane Bryce has authored 41 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 10 papers in Economics and Econometrics and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jane Bryce's work include Health Systems, Economic Evaluations, Quality of Life (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Economic and Financial Impacts of Cancer (7 papers). Jane Bryce is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (9 papers), Colorectal Cancer Treatments and Studies (7 papers) and Economic and Financial Impacts of Cancer (7 papers). Jane Bryce collaborates with scholars based in Italy, Canada and United States. Jane Bryce's co-authors include Massimo Di Maïo, Francesco Perrone, Mario E. Lacouture, Joel B. Epstein, Alexandre Chan, Beth Eaby‐Sandy, René‐Jean Bensadoun, Maria Carmela Piccirillo, Ethan Basch and Alessandro Morabito and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Annals of Oncology.

In The Last Decade

Jane Bryce

39 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

2015 330 citations Massimo Di Maïo, Ciro Gallo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jane Bryce Italy	19	978	408	355	239	212	41	1.8k
Norbert Marschner Germany	25	1.3k 1.3×	649 1.6×	407 1.1×	70 0.3×	124 0.6×	153	2.2k
V. Trillet-Lenoir France	27	1.5k 1.5×	356 0.9×	308 0.9×	146 0.6×	157 0.7×	105	2.4k
Patricia M. Jamison United States	13	1.4k 1.4×	505 1.2×	410 1.2×	64 0.3×	393 1.9×	19	2.5k
Susan Dent Canada	27	1.1k 1.1×	313 0.8×	315 0.9×	100 0.4×	63 0.3×	81	2.1k
Janina A. Longtine United States	27	703 0.7×	269 0.7×	367 1.0×	227 0.9×	240 1.1×	65	2.4k
Lucìa Mangone Italy	22	1.3k 1.3×	484 1.2×	345 1.0×	46 0.2×	211 1.0×	96	2.1k
Ellen G. Feigal United States	21	1.5k 1.6×	379 0.9×	735 2.1×	90 0.4×	477 2.3×	43	2.8k
Zeba Aziz Pakistan	22	1.2k 1.3×	326 0.8×	261 0.7×	48 0.2×	164 0.8×	73	2.0k
Paul R. Harnett Australia	28	880 0.9×	275 0.7×	554 1.6×	61 0.3×	96 0.5×	102	2.1k

Countries citing papers authored by Jane Bryce

Since Specialization

Citations

This map shows the geographic impact of Jane Bryce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Bryce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Bryce more than expected).

Fields of papers citing papers by Jane Bryce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Bryce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Bryce. The network helps show where Jane Bryce may publish in the future.

Co-authorship network of co-authors of Jane Bryce

This figure shows the co-authorship network connecting the top 25 collaborators of Jane Bryce. A scholar is included among the top collaborators of Jane Bryce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane Bryce. Jane Bryce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roncolato, Felicia, Madeleine King, Rachel O’Connell, et al.. (2024). Hidden in plain sight – Survival consequences of baseline symptom burden in women with recurrent ovarian cancer. Gynecologic Oncology. 185. 128–137. 3 indexed citations

Riva, Silvia, Mario Maio, Fabio Efficace, et al.. (2019). Measuring financial toxicity of cancer in the Italian health care system: Initial results of the patient reported outcome for fighting financial toxicity of cancer project (proFFiT). Annals of Oncology. 30. v681–v681. 1 indexed citations

Capoluongo, Ettore, Gillian Ellison, José Antonio López‐Guerrero, et al.. (2017). Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. Seminars in Oncology. 44(3). 187–197. 70 indexed citations

Maïo, Massimo Di, Ethan Basch, Jane Bryce, & Francesco Perrone. (2016). Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nature Reviews Clinical Oncology. 13(5). 319–325. 179 indexed citations

Perrone, Francesco, Claudio Jommi, Massimo Di Maïo, et al.. (2016). The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy. Annals of Oncology. 27(12). 2224–2229. 108 indexed citations

Maïo, Massimo Di, et al.. (2016). The effect of financial difficulties on clinical outcomes in Italian cancer patients: a pooled analysis of 16 academic prospective clinical trials. Annals of Oncology. 27. iv111–iv111. 1 indexed citations

Maïo, Massimo Di, Ciro Gallo, Natasha B. Leighl, et al.. (2015). Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. Journal of Clinical Oncology. 33(8). 910–915. 330 indexed citations breakdown →

Caminiti, Caterina, M. Bagnalasta, Fabio Arpinelli, et al.. (2015). Cross-cultural adaptation, evaluation and validation of the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE): a study protocol. Annals of Oncology. 26. vi127–vi127. 1 indexed citations

Bryce, Jane & Christine B. Boers‐Doets. (2014). Non-Rash Dermatologic Adverse Events Related to Targeted Therapies. Seminars in Oncology Nursing. 30(3). 155–168. 10 indexed citations

10.

Hasegawa, Kosei, Shoji Nagao, Masanori Yasuda, et al.. (2014). Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix. International Journal of Gynecological Cancer. 24(9 Suppl 3). S90–S95. 44 indexed citations

11.

Maïo, Massimo Di, Maria Carmela Piccirillo, Gennaro Daniele, et al.. (2014). Symptomatic Toxicities Experienced During Anti-Cancer Treatment: Comparison of Patients' and Physicians' Reporting in Three Randomized Controlled Trials (Rcts). Annals of Oncology. 25. iv517–iv517. 1 indexed citations

12.

Wong, Rebecca, René‐Jean Bensadoun, Christine B. Boers‐Doets, et al.. (2013). Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Supportive Care in Cancer. 21(10). 2933–2948. 177 indexed citations

13.

Vergote, Ignace, et al.. (2013). Roadmap for the European Network of Gynaecological Trial Groups (ENGOT) Trials. International Journal of Gynecological Cancer. 23(7). 1339–1343. 6 indexed citations

14.

Bryce, Jane, et al.. (2013). Nursing Management of Patients With Metastatic Melanoma Receiving Ipilimumab. Oncology nursing forum. 40(3). 215–218. 1 indexed citations

15.

Bauer, Martina, et al.. (2012). Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer. Breast Cancer Targets and Therapy. 4. 91–91. 18 indexed citations

16.

Daniele, Gennaro, Pasqualina Giordano, Antonella De Luca, et al.. (2011). Anticancer effect of bisphosphonates: new insights from clinical trials and preclinical evidence. Expert Review of Anticancer Therapy. 11(2). 299–307. 4 indexed citations

17.

Bryce, Jane, Martina Bauer, & Peyman Hadji. (2011). Aromatase Inhibitor-Associated Bone Loss. Oncology nursing forum. 38(3). 273–276. 3 indexed citations

18.

Morabito, Alessandro, Maria Carmela Piccirillo, Raffaele Costanzo, et al.. (2010). Vandetanib: An overview of its clinical development in NSCLC andother tumors. Drugs of today. 46(9). 683–683. 36 indexed citations

19.

Bryce, Jane, Marzia Falanga, Calogera Pisano, et al.. (2007). 8104 POSTER Expanding the role of the clinical research nurse in an Italian cooperative oncology research group. European Journal of Cancer Supplements. 5(4). 439–439.

20.

Caponigro, Francesco, Alfredo Budillon, Jane Bryce, et al.. (2000). Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer. Annals of Oncology. 11(3). 339–342. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact